Latest News and Press Releases
Want to stay updated on the latest news?
-
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
-
Transpire Bio Inc. has signed an exclusive license agreement with Suzhou Intragrand Pharma Co. for an investigational PDE4 inhibitor
-
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
-
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
-
Gyre's Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Liver Fibrosis Trial
-
Edesa Second Quarter Earnings Release 2025
-
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
-
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
-
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications